ReviewStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2018
Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer.
Review in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation.Thoracic cancer · 2019Trial
- A glimpse into the CyberKnife robotic radiosurgery system: technical specifications and developments during thirty years.Frontiers in oncology · 2026Review
- Small-volume plan optimization of inoperable early-stage centrally-located non-small-cell lung cancer using VMAT-based SBRT under the DIBH scenario: a single-arc model or a dual-arc plan?Frontiers in oncology · 2026Article
- Long-term clinical results of early-stage lung cancer patients treated with risk-adapted stereotactic body radiotherapy using LINAC or CyberKnife : A single-institution analysis of more than 400 cases.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Study of non-surgical therapeutic patterns and prognosis in elderly patients with stage II non-small-cell lung cancer: an investigational study based on the SEER database.Translational cancer research · 2025Article
- Research Progress of SBRT Combined With Immunotherapy in Locally Advanced Head and Neck Cancer.American journal of clinical oncology · 2025Review
- Article
- Review
- Results of Stereotactic Body Radiotherapy With CyberKnife-M6 for Primary and Metastatic Lung Cancer.World journal of oncology · 2024Article
- How AI and Robotics Will Advance Interventional Radiology: Narrative Review and Future Perspectives.Diagnostics (Basel, Switzerland) · 2024Review
- [Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Application of real-time MRI-guided linear accelerator in stereotactic ablative body radiotherapy for non-small cell lung cancer: one step forward to precise targeting.Journal of cancer research and clinical oncology · 2022Article
- High-dose stereotactic body radiotherapy using CyberKnife® for stage I peripheral lung cancer: a single-center retrospective study.Radiation oncology (London, England) · 2022Article
- Verification of an optimizer algorithm by the beam delivery evaluation of intensity-modulated arc therapy plans.Radiology and oncology · 2021Article
- Combining computed tomography and biologically effective dose in radiomics and deep learning improves prediction of tumor response to robotic lung stereotactic body radiation therapy.Medical physics · 2021Article
- Using the Diaphragm as a Tracking Surrogate in CyberKnife Synchrony Treatment.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Radiation-Induced Dyspnea in Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy.Cancers · 2021Article
- Radiomics for prediction of radiation-induced lung injury and oncologic outcome after robotic stereotactic body radiotherapy of lung cancer: results from two independent institutions.Radiation oncology (London, England) · 2021Article
- Radiofrequency ablationJournal of Cancer · 2021Article
- Stereotactic body radiation therapy using CyberKnife for T1N0M0 lung cancer patients with severe pulmonary dysfunction.Journal of radiation research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate efficacy and toxicity of stereotactic body radiation therapy (SBRT) with CyberKnife® (Accuray, Sunnyvale, CA, USA) in a selected cohort of primary, medically inoperable early-stage non-small cell lung cancer (NSCLC) patients.
methodsFrom 2012 to 2016, 106 patients (median age 74 years, range 50-94 years) with primary NSCLC were treated with SBRT using CyberKnife®. Histologic confirmation was available in 87 patients (82%). For mediastinal staging, 92 patients (87%) underwent
resultsMedian follow-up was 15 months (range 0.5-46 months). Acute side effects were mild (fatigue grade 1-2 in 20% and dyspnea grade 1-2 in 17%). Late effects were observed in 4 patients (4%): 3 patients developed pneumonitis requiring therapy (grade 2) and 1 patient suffered a rib fracture (grade 3). In total, 9/106 patients (8%) experienced a local recurrence, actuarial local control rates were 88% (95% confidence interval, CI, 80-96%) at 2 years and 77% (95%CI 56-98%) at 3 years. The median disease-free survival time was 27 months (95%CI 23-31 months). Overall survival was 77% (95%CI 65-85%) at 2 years and 56% (95%CI 39-73%) at 3 years.
conclusionCyberKnife® lung SBRT which allows for real-time tumor tracking and risk-adapted fractionation achieves satisfactory local control and low toxicity rates in inoperable early-stage primary lung cancer patients.
Indexed as
Identifiers
28812120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.